Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

Benzinga_recent_news11-17

XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ:RPTX). Repare shareholders will receive a cash payment...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584627449?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/17/MA.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-11-17 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584627449","market":"us","top_or_hot":-1,"title":"Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value","media":"Benzinga_recent_news","content":"<div>\n<p>XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ:RPTX).\nRepare shareholders will receive a cash payment...</p>\n\n<a href=\"https://www.benzinga.com/m-a/25/11/48900667/repare-therapeutics-agrees-to-acquisition-as-board-cites-best-path-for-stakeholder-value\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRepare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-17 23:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/m-a/25/11/48900667/repare-therapeutics-agrees-to-acquisition-as-board-cites-best-path-for-stakeholder-value><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ:RPTX).\nRepare shareholders will receive a cash payment...</p>\n\n<a href=\"https://www.benzinga.com/m-a/25/11/48900667/repare-therapeutics-agrees-to-acquisition-as-board-cites-best-path-for-stakeholder-value\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/m-a/25/11/48900667/repare-therapeutics-agrees-to-acquisition-as-board-cites-best-path-for-stakeholder-value","article_id":"2584627449","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/17/MA.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/m-a/25/11/48900667/repare-therapeutics-agrees-to-acquisition-as-board-cites-best-path-for-stakeholder-value","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584627449","pubTimestamp":1763393040,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Repare Therapeutics agrees to be acquired by XenoTherapeutics, offering shareholders cash, CVRs, and future milestone potential as the deal targets an early 2026 closing.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RPTX":"Repare Therapeutics Inc."},"translate_title":"Repare Therapeutics同意收购，因为董事会引用了利益相关者价值的最佳途径","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPTX":1.5},"content_text":"XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ:RPTX).\nRepare shareholders will receive a cash payment per Common Share, determined based on Repare’s cash balance at closing of the transaction, after deducting certain transaction costs and the aggregate amount of outstanding liabilities.\nBased on Repare’s current estimates, each Repare shareholder will receive a cash payment of $1.82 per Common Share.\nIn addition, each Repare shareholder will receive one non-transferable contingent value right for each Common Share, entitling the holder to certain cash payments.\n“Following a thorough and wide-ranging strategic review of potential opportunities, partnerships and transactions aimed at maximizing shareholder value, Repare’s Board of Directors has unanimously determined that the Transaction is in the best interests of Repare and its various stakeholders,” said Steve Forte, president, CEO and CFO of Repare. “The Transaction provides a cash payment to shareholders and the opportunity for continued participation in milestones and royalties from existing and potential future partnerships.”\nThe transaction is expected to close in the first quarter of 2026.\nThe arrangement agreement includes a termination fee of $2 million, payable by Repare Therapeutics.\nIn May, Repare Therapeutics out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation.\nAdditionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal, and acquire certain laboratory equipment.\nUnder the terms of the out-licensing agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% common equity position in DCx, and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low-single digit tiered sales royalties for the development of specific products by DCx.\nIn July 2025, Repare entered into an exclusive worldwide licensing agreement with Debiopharm International for lunresertib.\nUnder the terms of the agreement, Repare will receive a $10 million upfront payment and is eligible to receive up to $257 million in potential clinical, regulatory, commercial, and sales milestones, including up to $5 million in potential near-term payments, as well as single-digit royalties on global net sales.\nPrice Action: RPTX stock is up 25.15% to $2.065 in the premarket at the last check on Monday.\nRead Next:\nPhoto: Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584627449","isCrawlerRequest":true}